Such excellent LOD is 2–3 orders of magnitude lower than the clinically relevant PSA levels present in biological samples (4–10 ng·mL−1) and even to monitor eventual recurrence after clinical treatment of a prostate tumor (0.1 ng·mL−1). This evidence concerns the gene KLK3 and prostate neoplasm.